Company intelligence / Profile preview
Promiliad Biopharma
Alberton, Montana, United Statespromiliad.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Promiliad developed multiple antibiotic programs through NIH funding, including DHFR inhibitors, triazolononactate antibiotics, and platensimycin/platencin derivatives. The company successfully licensed its DHFR inhibitor program to Spero Therapeutics in 2016.
- Therapeutic areas
- Infectious DiseasesPsychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of ConnecticutUniversity of FloridaOhio UniversityUniversity of MontanaSpero Therapeutics
Beyond the preview
Go deeper on Promiliad Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Promiliad Biopharma.